Evidence map›Paper›PMID 26483473›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

Maternal CD4+ T cells protect against severe congenital cytomegalovirus disease in a novel nonhuman primate model of placental cytomegalovirus transmission.

Kristy M Bialas, Takayuki Tanaka, Dollnovan Tran, Valerie Varner, Eduardo Cisneros De La Rosa, Flavia Chiuppesi, Felix Wussow, Lisa Kattenhorn, Sheila Macri, Erika L Kunz and 12 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 111 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Decidual CD4 Effector Memory and Resident Memory T Cells Respond to Cord Blood Allo-Antigens.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Article
  6. Dysfunctional decidual CD2Frontiers in immunology · 2026
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. A vaccine against cytomegalovirus: how close are we?The Journal of clinical investigation · 2025
    Article
  16. Article
  17. Article
  18. Review
  19. Pathogenesis of viral infections during pregnancy.Clinical microbiology reviews · 2024
    Review
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 1 country.

Kristy M BialasDuke Human Vaccine Institute, Duke University Medical School, Durham, NC 27710;
Takayuki TanakaNew England Primate Research Center, Harvard Medical School, Southborough, MA 01772;
Dollnovan TranNew England Primate Research Center, Harvard Medical School, Southborough, MA 01772; Tulane National Primate Research Center, Tulane University, Covington, LA 70433;
Valerie VarnerNew England Primate Research Center, Harvard Medical School, Southborough, MA 01772;
Eduardo Cisneros De La RosaDuke Human Vaccine Institute, Duke University Medical School, Durham, NC 27710;
Flavia ChiuppesiDepartment of Experimental Therapeutics, Beckman Research Institute of the City of Hope, Duarte, CA 91010;
Felix WussowDepartment of Experimental Therapeutics, Beckman Research Institute of the City of Hope, Duarte, CA 91010;
Lisa KattenhornNew England Primate Research Center, Harvard Medical School, Southborough, MA 01772;
Sheila MacriNew England Primate Research Center, Harvard Medical School, Southborough, MA 01772;
Erika L KunzDuke Human Vaccine Institute, Duke University Medical School, Durham, NC 27710;
Judy A EstroffDepartment of Radiology, Boston's Children Hospital, Boston, MA 02115;
Jennifer KirchherrDuke Human Vaccine Institute, Duke University Medical School, Durham, NC 27710;
Yujuan YueCenter for Comparative Medicine, Department of Pathology and Laboratory Medicine, University of California, Davis, CA 95616;
Qihua FanDuke Human Vaccine Institute, Duke University Medical School, Durham, NC 27710;
Michael LauckDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53711;
David H O'ConnorDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53711; Wisconsin National Primate Research Center, University of Wisconsin, Madison, WI 53711;
Allison H S HallDepartment of Pathology, Duke University, Durham, NC 27710.
Alvarez XavierTulane National Primate Research Center, Tulane University, Covington, LA 70433;
Don J DiamondDepartment of Experimental Therapeutics, Beckman Research Institute of the City of Hope, Duarte, CA 91010;
Peter A BarryCenter for Comparative Medicine, Department of Pathology and Laboratory Medicine, University of California, Davis, CA 95616;
Amitinder KaurNew England Primate Research Center, Harvard Medical School, Southborough, MA 01772; Tulane National Primate Research Center, Tulane University, Covington, LA 70433; Sallie.permar@duke.edu akaur@tulane.edu.
Sallie R PermarDuke Human Vaccine Institute, Duke University Medical School, Durham, NC 27710; Sallie.permar@duke.edu akaur@tulane.edu.
Duke Medical Center · USHarvard University · USBeckman Research InstituteNew England Biolabs (United States) · USTulane University · USUniversity of California, Davis · USUniversity of Wisconsin–Madison · USBoston Children's Museum · USCity of Hope · USDuke University · US

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
New England Primate Research Center Base GrantP51OD011103 · OD · HARVARD MEDICAL SCHOOL · PI FLIER, JEFFREY S · 2012 to 2013
$24.7M
Nonhuman Primate Reagent ResourceU24AI126683 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2016 to 2026
$20.1M
Ruth L. Kirschstein National Research Service Award (NRSA)- T32T32AI007392 · NIAID · DUKE UNIVERSITY · PI Amy Lynn Corneli, Guido Ferrari · 1990 to 2026
$9.8M
Peptide Vaccine To Prevent CMV Disease After HSCTR01CA077544 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI DIAMOND, DON J · 1998 to 2017
$5.6M
Resource for Nonhuman Primate Immune ReagentsR24OD010947 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI VILLINGER, FRANCOIS J · 2012 to 2025
$4.9M
Resource for Nonhuman Primate Cell Depleting AntibodiesR24OD010976 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ENGELMAN, KATHLEEN, MAGNANI, DIOGO · 2012 to 2019
$4.7M
CMVPepVax to Protect HCT Recipients from Cytomegalovirus InfectionR01CA181045 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI DIAMOND, DON J · 2014 to 2018
$3.6M
Maternal immune protection against congenital CMV infectionDP2HD075699 · NICHD · DUKE UNIVERSITY · PI PERMAR, SALLIE R. · 2012 to 2017
$2.8M
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast EntryR01AI103960 · NIAID · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BARRY, PETER A, DIAMOND, DON J · 2013 to 2016
$2.8M
NCCDPHP CDC HHS 1DP2-HD075699NCI NIH HHS CA077544NCI NIH HHS CA181045NCI NIH HHS R01 CA077544NCI NIH HHS R01 CA181045NIAID NIH HHS 5 T32 AI7392-24NIAID NIH HHS AI103960NIAID NIH HHS R01 AI103960NIAID NIH HHS T32 AI007392NIAID NIH HHS U24 AI126683NICHD NIH HHS DP2 HD075699NIH HHS P51 OD011103NIH HHS P51OD011103NIH HHS P51 OD011104NIH HHS P51 OD011107NIH HHS R24 OD010947NIH HHS R24 OD010976
6 · The paper itself

Abstract

Elucidation of maternal immune correlates of protection against congenital cytomegalovirus (CMV) is necessary to inform future vaccine design. Here, we present a novel rhesus macaque model of placental rhesus CMV (rhCMV) transmission and use it to dissect determinants of protection against congenital transmission following primary maternal rhCMV infection. In this model, asymptomatic intrauterine infection was observed following i.v. rhCMV inoculation during the early second trimester in two of three rhCMV-seronegative pregnant females. In contrast, fetal loss or infant CMV-associated sequelae occurred in four rhCMV-seronegative pregnant macaques that were CD4(+) T-cell depleted at the time of inoculation. Animals that received the CD4(+) T-cell-depleting antibody also exhibited higher plasma and amniotic fluid viral loads, dampened virus-specific CD8(+) T-cell responses, and delayed production of autologous neutralizing antibodies compared with immunocompetent monkeys. Thus, maternal CD4(+) T-cell immunity during primary rhCMV infection is important for controlling maternal viremia and inducing protective immune responses that prevent severe CMV-associated fetal disease.

Indexed as

Infectious Disease Transmission, VerticalMaternal-Fetal ExchangeAnimalsAntibodies, ViralCD4-Positive T-LymphocytesCytomegalovirus InfectionsDisease Models, AnimalFemaleMacaca mulattaPregnancyAntibodies, Viralcongenital cytomegalovirusneutralizing antibodyrhesus CMVrhesus modelT-cell immunity

Identifiers

PMID26483473
PMCPMC4640765
OpenAlexW2228972936

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.